Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O75352
UPID:
MPU1_HUMAN
Alternative names:
Suppressor of Lec15 and Lec35 glycosylation mutation homolog
Alternative UPACC:
O75352; B3KQP1; B4DT74; Q9BUU8
Background:
The Mannose-P-dolichol utilization defect 1 protein, also known as the Suppressor of Lec15 and Lec35 glycosylation mutation homolog, plays a pivotal role in glycoprotein biosynthesis. It is essential for the normal utilization of mannose-dolichol phosphate in the synthesis of N-linked and O-linked oligosaccharides and GPI anchors, which are crucial for protein folding and stability.
Therapeutic significance:
Linked to Congenital disorder of glycosylation 1F, this protein's dysfunction manifests in a wide array of clinical features, including developmental and neurological disorders. Understanding its role could pave the way for innovative treatments targeting the underlying glycosylation defects.